Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 666Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Lymphoma, Follicular 418Lymphoma, Large B-Cell, Diffuse 379Leukemia 358Hodgkin Disease 354Lymphoma, Mantle-Cell 306Leukemia, Myeloid, Acute 250Multiple Myeloma 237Myelodysplastic Syndromes 214Lymphoma, B-Cell, Marginal Zone 196Recurrence 195Burkitt Lymphoma 189Waldenstrom Macroglobulinemia 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 130Lymphoma, B-Cell 127Neoplasms 118Lymphoma, T-Cell, Cutaneous 116Lymphoma, Large-Cell, Anaplastic 113Hematologic Neoplasms 103Lymphoma, Large-Cell, Immunoblastic 100Mycosis Fungoides 95Myeloproliferative Disorders 94Sezary Syndrome 86Lymphoma, T-Cell, Peripheral 83Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 74Primary Myelofibrosis 70

Interventions

vistusertib 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × DLBCL × Lymphoid × Clear all
NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated
25 enrolled 11 charts
Lymphoid

DLBCL

Data powered by HemOnc (CC BY 4.0) Colophon âš¡